Advancing Therapies from Discovery to Patients Through Novel Target Evaluation, Validation of Meaningful Surrogate Endpoints, & Optimized Patient Stratification to be the First to Market in New Indications
As competition intensifies across rare and genetic kidney disease pipelines, companies are under increasing pressure to differentiate assets, generate robust clinical data, and accelerate timelines to market. Across IgAN, FSGS, ADPKD, Alport syndrome, and C3G, accelerated approval pathways have reshaped how teams approach target validation, endpoint selection, and trial design in small and heterogeneous patient populations. However, persistent challenges in patient recruitment, uncertainty in surrogate endpoints, and incomplete disease biology continue to slow progress. With more programs advancing than ever before, teams must make faster, higher‑stakes decisions, driving demand for stronger translational models, better patient stratification, and more efficient clinical trial designs.
The 6th Rare & Genetic Kidney Disease Drug Development Summit brings together leading experts across biopharma, academia, and patient advocacy to address these barriers head-on. Drawing on experience from organizations advancing approved and late-stage therapies, including Novartis, Calliditas, and Travere Therapeutics, this meeting spans discovery through commercialization and provides a focused forum to share real-world data, pressure-test development strategies, and align on what it takes to advance renal disease therapies.
Join the community advancing the next generation of kidney therapies and leave with practical insights you can apply directly to your programs.
There is such a sense of camaraderie at the Rare & Genetic Kidney Disease Drug Development Summit. All stakeholders understand the significant unmet needs and are working collaboratively to advance the field. This meeting is a great way to quickly build knowledge, insights, and connections
Executive Director, Alport Syndrome Foundation
The overall openness to share information and interact with others with an interest in rare kidney diseases made this a valuable and collaborative experience
Director - Early Development, Calliditas Therapeutics
Speakers are excellent and the topics are well-chosen. The speed networking rounds are a really great way to meet people and companies.
Owner, Trillium Medical Ventures
It was a well planned, well developed conference with pertinent information presented.
Explore the Full Event Guide
- See how companies are tackling challenges from preclinical target validation through clinical development, payer engagement, and asset evaluation
- Preview strategies across 5+ rare kidney disease indications
- Insights from the companies and experts advancing renal pipelines
- Learn how teams are addressing surrogate endpoints, clinical trial design, and patient recruitment
- Share key insights with internal stakeholders to align your team
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest breakthroughs in biomarker validation, surrogate endpoints, and clinical trial design through a packed agenda featuring 3 expert panel discussions, 3 pre-conference workshops, 2 interactive roundtables, and 12+ data-driven case study presentations.
Partner With Us
Position yourself alongside leading solution providers supporting rare and genetic kidney disease pipelines. Whether your expertise lies in preclinical or clinical research, novel biomarkers for diagnosis, stratification or monitoring, imaging, or genetic testing, ensure your brand is at the center of key conversations around clinical development, endpoint validation, and trial execution
Join Biopharma Experts
Engage with a uniquely focused audience of rare and genetic kidney disease decision-makers and be part of high-value conversations with like-minded attendees across all stages of drug development, building critical connections through dedicated networking opportunities